Anti-obesity drugs found to benefit kidney transplant recipients with type 2 diabetes

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows. Not only is obesity a known risk factor for diabetes, but it also increases risk of postsurgical complications, such as inflammation, organ rejection, and early death.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup